Abstract: The present invention is directed to a biologically active CSF-1 dimer comprising a first CSF-1 monomer and a second CSF-1 monomer, wherein at least one of the monomers is truncated at the C-terminus after residue position 223. The dimers also include point mutations in one or both of the CSF-1 monomer. The invention also includes pharmaceutical compositions that comprise the CSF-1 dimer in a pharmaceutical excipient.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
January 19, 1999
Assignee:
Chiron Corporation
Inventors:
Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird